We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.95B
AUM Growth
-$1.05B
Cap. Flow
+$64.3M
Cap. Flow %
1.08%
Top 10 Hldgs %
34.22%
Holding
172
New
36
Increased
33
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$126M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$126M
3
PASG icon
Passage Bio
PASG
+$109M
4
PFE icon
Pfizer
PFE
+$108M
5
CNC icon
Centene
CNC
+$81M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$372M
2
ARQL
Arqule Inc
ARQL
+$99.8M
3
DHR icon
Danaher
DHR
+$98.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$79.2M
5
INSP icon
Inspire Medical Systems
INSP
+$74M

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Financials 1.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$46.7B
$88M 1.48%
280,300
-111,600
-28% -$37.6M
ISRG icon
27
Intuitive Surgical
ISRG
$130B
$83.7M 1.41%
507,300
+3,900
+0.8% +$714K
CNC icon
28
Centene
CNC
$31.6B
$79.4M 1.33%
+1,335,700
New +$81M
CI icon
29
Cigna
CI
$79.6B
$77.9M 1.31%
439,700
-50,000
-10% -$9.7M
BLU
30
DELISTED
BELLUS Health Inc.
BLU
$69.4M 1.17%
7,025,832
– –
HZNP
31
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$69.4M 1.17%
2,341,700
+759,400
+48% +$25.7M
HCA icon
32
HCA Healthcare
HCA
$92.8B
$63.8M 1.07%
709,800
+519,800
+274% +$67.3M
SYK icon
33
Stryker
SYK
$133B
$61.8M 1.04%
+371,100
New +$72.5M
AGIO icon
34
Agios Pharmaceuticals
AGIO
$2.14B
$58.6M 0.99%
+1,652,696
New +$76.4M
EXEL icon
35
Exelixis
EXEL
$14.2B
$54.8M 0.92%
3,180,100
-573,600
-15% -$10.5M
PTCT icon
36
PTC Therapeutics
PTCT
$6.25B
$51.2M 0.86%
1,148,723
-580,477
-34% -$29.2M
MGTX icon
37
MeiraGTx Holdings
MGTX
$1.09B
$48.1M 0.81%
3,582,320
+129,300
+4% +$2.18M
GKOS icon
38
Glaukos
GKOS
$8.89B
$47.8M 0.8%
1,547,646
– –
DCPH
39
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$47.7M 0.8%
1,157,600
-356,571
-24% -$19.8M
KALA icon
40
KALA BIO
KALA
$12.3M
$47.5M 0.8%
2,163
+782
+57% +$12.5M
QURE icon
41
uniQure
QURE
$2.52B
$46.7M 0.78%
983,979
-97,786
-9% -$5.62M
BMRN icon
42
BioMarin Pharmaceuticals
BMRN
$12B
$45.7M 0.77%
540,500
+505,800
+1,458% +$43.6M
ELVN icon
43
Enliven Therapeutics
ELVN
$3.84B
$43.6M 0.73%
+679,976
New +$43.3M
APLT
44
DELISTED
Applied Therapeutics
APLT
$43.1M 0.73%
1,319,877
+332,691
+34% +$13.5M
ARVN icon
45
Arvinas
ARVN
$529M
$40.1M 0.67%
995,000
-903,800
-48% -$42.3M
BHC icon
46
Bausch Health
BHC
$1.69B
$37.2M 0.63%
2,399,880
-783,220
-25% -$18.9M
ADVM
47
DELISTED
Adverum Biotechnologies
ADVM
$33.7M 0.57%
345,064
-89,155
-21% -$10.4M
EW icon
48
Edwards Lifesciences
EW
$48.2B
$33.3M 0.56%
530,400
-774,300
-59% -$55.8M
LOGC
49
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$31.9M 0.54%
6,466,783
– –
TMO icon
50
Thermo Fisher Scientific
TMO
$214B
$31.3M 0.53%
110,300
-110,200
-50% -$34.7M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2020 Portfolio in Review

As of Q1 2020, OrbiMed held 172 positions worth $5.95B, down 15% from $7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2020 filing shows 36 new, 33 increased, 28 reduced and 30 closed positions. Its largest new stake was Arcutis Biotherapeutics: 4,673,850 shares worth $139M. The largest sale was Synthorx, Inc. Common Stock, an estimated $372M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2020 buy was Arcutis Biotherapeutics: 4,673,850 shares worth $139M.
  • OrbiMed added most to Biogen in Q1 2020, an estimated $126M increase.
  • OrbiMed's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $79.2M.
  • OrbiMed fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $372M.
  • OrbiMed's ten largest holdings make up 34% of its $5.95B portfolio in Q1 2020.
  • OrbiMed opened 36 new positions and closed 30 in Q1 2020.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $5.95B.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.